808756-83-4

Usage

Uses

Used in Organic Synthesis:
(1R)-5-tert-Butyl-2,3-dihydro-1H-inden-1-amine is used as a building block in organic synthesis for the creation of various complex organic molecules. Its unique structure and reactivity make it a valuable component in the synthesis of pharmaceuticals and other specialty chemicals.
Used in Pharmaceutical Industry:
(1R)-5-tert-Butyl-2,3-dihydro-1H-inden-1-amine is used as a potential active pharmaceutical ingredient (API) for the development of new drugs. Its structural features and reactivity may contribute to the discovery of novel therapeutic agents with unique mechanisms of action.
Used in Materials Science:
(1R)-5-tert-Butyl-2,3-dihydro-1H-inden-1-amine is used as a component in the development of new materials with specific properties. Its unique structure and potential reactivity may contribute to the creation of advanced materials for various applications, such as coatings, adhesives, or polymers.
Further research is needed to fully understand the properties and potential uses of (1R)-5-tert-Butyl-2,3-dihydro-1H-inden-1-amine, as its applications in these fields are currently speculative and based on its structural features and potential reactivity.

Upstream product

• 935680-90-3 5-tert-butyl-2,3-dihydro-1H-inden-1-ylamine 
• 935680-89-0 5-tert-butyl-1-indanone O-methyloxime 
• 104-15-4 toluene-4-sulfonic acid 
• 1374781-07-3 (Z)-5-tert-butyl-2,3-dihydro-1H-inden-1-one oxime 
• 28547-33-3 1-(4-(tert-butyl)phenyl)-3-chloropropan-1-one 
• 4600-86-6 5-(tert-butyl)-2,3-dihydro-1H-inden-1-one 
• 253185-03-4 tert-butylbenzene 
• 1056038-54-0 (Z)-5-tert-butyl-2,3-dihydro-1H-inden-1-one O-methyl oxime 

Downstream Products

• 934593-36-9 (1R)-5-tert-butyl-indan-1-ylamine tosylate 

Relevant academic research and scientific papers

SUBSTITUTED BICYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted bicyclic carboxamide and urea derivatives, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions.

Substituted Bicyclic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands

Substituted bicyclic carboxamide and urea compounds corresponding to formula (I) processes for the preparation thereof, pharmaceutical compositions containing these compounds, and a method of using these compounds for the treatment and/or inhibition of pain and other conditions mediated at least in part via the vanilloid receptor 1.

Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H- indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management

Vanilloid receptor TRPV1 is a cation channel that can be activated by a wide range of noxious stimuli, including capsaicin, acid, and heat. Blockade of TRPV1 activation by selective antagonists is under investigation by several pharmaceutical companies in an effort to identify novel agents for pain management. Here we report that replacement of substituted benzyl groups by an indan rigid moiety in a previously described N-indazole-N′-benzyl urea series led to a number of TRPV1 antagonists with significantly increased in vitro potency and enhanced drug-like properties. Extensive evaluation of pharmacological, pharmacokinetic, and toxicological properties of synthesized analogs resulted in identification of (R)-7 (ABT-102). Both the analgesic activity and drug-like properties of (R)-7 support its advancement into clinical pain trials.

Prodrugs of compounds that inhibit TRPV1 receptor

Compounds of formula (I) wherein A, R1, R2, and R3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladd

Development of a large scale asymmetric synthesis of vanilloid receptor (TRPV1) antagonist ABT-102

A highly efficient asymmetric synthesis of TRPV1 antagonist ABT-102 was developed and successfully demonstrated on a multi-kilogram scale. This process incorporates a new asymmetric synthesis of (R)-tert-butylaminoindan, which is based on a chiral auxiliary induced diastereoselective reduction of its iminoindan precursor.

Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.